Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 E6011 in Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid
jRCT2080223460Phase 2Terminated
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing E6011 intravenous with Placebo intravenous (2 arms). Started Mar 2017; status: terminated.
02
Drugs
quetmolimab
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on jRCT2080223460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223460.